Key Takeaways

Older diabetic patients on two GLP-1 drugs showed an increased risk of neovascular age-related macular degeneration in an observational cohort study.

The absolute risk was small, however, reaching 0.2% at 3 years among GLP-1 medication users and 0.1% among non-users.

Semaglutide represented the bulk of GLP-1 receptor agonists used in the study, hence the need for further investigation in this drug class.

Older adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their risk of developing neovascular age-related macular degeneration (nAMD), according to a retrospective, population-based cohort study from Canada.

Patients taking GLP-1 agonists for type 2 diabetes for at least 6 months had an excess risk of nAMD comp

See Full Page